• RenovoRx announced a peer-reviewed case series publication on its TAMP platform using the RenovoCath device in locally advanced pancreatic cancer.
• Results were presented in the journal publication, not flagged for a future conference presentation.
• Two heavily pretreated patients showed evidence of tumor response, including improved disease markers and supportive imaging changes.
• No major procedure-related complications were reported, supporting further evaluation of the localized drug-delivery approach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010830PRIMZONEFULLFEED9837397) on October 01, 2026, and is solely responsible for the information contained therein.